ID

34411

Descrição

Non-interventional Study With Pomalidomide (Imnovid®); ODM derived from: https://clinicaltrials.gov/show/NCT02075996

Link

https://clinicaltrials.gov/show/NCT02075996

Palavras-chave

  1. 17/01/2019 17/01/2019 -
Titular dos direitos

see on clinicaltrials.gov

Transferido a

17 de janeiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Multiple Myeloma NCT02075996

Eligibility Multiple Myeloma NCT02075996

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with relapsed or refractory multiple myeloma patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen
Descrição

ID.1

Tipo de dados

boolean

adult male and female patients (at least 18 years with no upper age limit)
Descrição

ID.2

Tipo de dados

boolean

written informed consent to data collection and pseudonymized data transfer
Descrição

ID.3

Tipo de dados

boolean

the conditions of the pregnancy prevention programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics imnovid®)
Descrição

ID.4

Tipo de dados

boolean

other criteria according to summary of product characteristics imnovid®
Descrição

ID.5

Tipo de dados

boolean

Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
missing patient's informed consent
Descrição

ID.6

Tipo de dados

boolean

pregnant or breast-feeding women
Descrição

ID.7

Tipo de dados

boolean

male patients, not capable of complying the required preventive measures (see summary of product characteristics imnovid®)
Descrição

ID.8

Tipo de dados

boolean

other criteria according to summary of product characteristics imnovid®
Descrição

ID.9

Tipo de dados

boolean

Similar models

Eligibility Multiple Myeloma NCT02075996

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with relapsed or refractory multiple myeloma patients must have received at least two prior lines of treatment (induction therapy followed by stem cell transplantation ± maintenance therapy is considered one prior therapy) and must have progressed under the most recent therapy regimen
boolean
ID.2
Item
adult male and female patients (at least 18 years with no upper age limit)
boolean
ID.3
Item
written informed consent to data collection and pseudonymized data transfer
boolean
ID.4
Item
the conditions of the pregnancy prevention programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential (see summary of product characteristics imnovid®)
boolean
ID.5
Item
other criteria according to summary of product characteristics imnovid®
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
missing patient's informed consent
boolean
ID.7
Item
pregnant or breast-feeding women
boolean
ID.8
Item
male patients, not capable of complying the required preventive measures (see summary of product characteristics imnovid®)
boolean
ID.9
Item
other criteria according to summary of product characteristics imnovid®
boolean

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial